

1343 Highlights

Editorial

Pour la version française de l'éditorial, veuillez consulter la page 1387.

- 1345 Cruel and usual punishment: solitary confinement in Canadian prisons.** Long-term health effects of solitary confinement may affect the offender's ability to reintegrate into society upon release.
D. Kelsall

Commentary

- 1347 Adding the head-tilt–chin-lift technique to adult compression-only CPR by untrained bystanders.** Rescue breathing (consisting of the head-tilt–chin-lift technique plus mouth-to-mouth ventilation) was eliminated from the guidelines to make CPR easier for untrained lay people.
A.M.-H. Ho, S. Wan, D.C. Chung

News

- 1350 Continued high use of PPIs despite *C. difficile* risk**
C. Brown
- 1351 Canada tackles antimicrobial resistance**
T. Murray
- 1352 Addressing bias in industry-funded CME**
R. Collier
- 1353 Medical technology: the good and the bad**
R. Collier
- 1354 Lyme law uses “junk science” says expert**
C. Brown

Research

Pour les versions françaises de ces résumés, veuillez consulter les pages 1387–90.

- 1358 Oral administration of morphine versus ibuprofen to manage postfracture pain in children: a randomized trial.** In this study, morphine was associated with a significantly greater number of adverse effects.
N. Poonai, G. Bhullar, K. Lin, A. Papini, D. Mainprize, J. Howard, J. Teefy, M. Bale, C. Langford, R. Lim, L. Stitt, M.J. Rieder, S. Ali

Synopses

- 1364 Time trends in symptoms of mental illness in children and adolescents in Canada.** Symptoms of mental illness (with the exception of hyperactivity) may not be increasing among Canadian adolescents.
S.E. McMartin, M. Kingsbury, J. Dykxhoorn, I. Colman
- 1365 What really matters in end-of-life discussions? Perspectives of patients in hospital with serious illness and their families.** Guideline-recommended elements of goals-of-care discussions are not often addressed by health care providers.
J.J. You, P. Dodek, F. Lamontagne, J. Downar, T. Sinuff, X. Jiang, A.G. Day, D.K. Heyland; the ACCEPT Study Team and the Canadian Researchers at the End of Life Network (CARENET)

1368 Research in CMAJ Open

- Highlights**
Undiagnosed diabetes and quality of care
Life-ending acts without explicit request



1345



1347



1350



1354



1364



1365

All editorial matter in *CMAJ* represents the opinions of the authors and not necessarily those of the Canadian Medical Association (CMA). The CMA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CMAJ* including editorials, studies, reports, letters and advertisements.

Review

- 1369 Deprescribing for older patients.**
CME Physicians should identify drugs that are no longer indicated, inappropriate or do not align with goals of care.
C. Frank, E. Weir

Analysis

- 1379 Regulatory decisions pertaining to aprotinin may be putting patients at risk.** BART authors suggest that the prudent regulatory response to any uncertainty would be to mandate a second large trial comparing aprotinin to an active agent.
P.C. Hébert, D.A. Fergusson, B. Hutton, C.D. Mazer, S. Fremes, M. Blajchman, C. MacAdams, G. Wells, J. Robblee, J. Bussièrès, K. Teoh; the BART Investigators

1387 Dans le JAMC

Practice

Decisions

- 1391 Imaging in a 35-year-old woman with progressive headache.** Don't do imaging for uncomplicated headache unless red flags are present.
S. Chakraborty, W.D. Miller

Five things to know about ...

- 1394 Screening with the Pap test.** Deaths from invasive cervical cancer occur mostly among women who do not undergo regular screening.
D. Ponka, J. Dickinson

Clinical images

- 1395 Brown-Séquard syndrome from herniation of a thoracic disc.** A healthy 36-year-old man presented to the emergency department with a painless and progressive left footdrop, numbness in the right leg and urinary hesitancy for 10 days.
C.D. Witiv, M.F. Shamji

CME Go to cmaj.ca to learn about obtaining CME credits.

1397 Letters

Atypical diabetes: clarifying the muddy waters

E. Sellers, S. Marks, C. Rodd, R. Wicklow, H. Dean; D. Steenkamp, S. Alexanian, E. Sternthal

Beyond resuscitate and do-not-resuscitate

J. Simon, E. Wasylenko, D. Barwich; P.C. Hébert, D. Selby

About bloody time

E.S. Weiss

Holiday Reading

Department of advice

1400 Limitations

R. Collier

Unsubstantiated theory

1402 Evidence-based dating: the Johnson-Purdy nomogram

E. Purdy, H. Johnson

1404 Diving into the ice bucket challenge

A. Adishes, S. Melville, T. Pulinilkunnil, S. Lutchmedial, K.R. Brunt

In other words

1406 TYPE-Os

D. Amato

1424 Digestif

Resources


- 1409 Career/Classified advertising
1420 CMA Bulletin
1421 Bulletin de l'AMC
1422 In memoriam




1369



1379




1395



1397






1404

 **THE NOVARTIS COPD PORTFOLIO**

NOVARTIS
PHARMACEUTICALS

Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9S 1A9
www.novartis.ca
514 631 6775 • 514 631 1867

SEEBRI, ONBREZ, ULTIBRO and BREEZHALER are registered trademarks.
Product Monographs available on request.
14SEE034E
© Novartis Pharmaceuticals Canada Inc. 2014

Member
PAB® R&D